The use of B vitamins to prevent cognitive decline in older mild cognitive impairment patients with elevated plasma homocysteine - A randomized placebo controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003302

Enrollment

Unknown

Registered

2013-07-04

Start date

2013-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Interventions

Two groups:Vitamin B12 and Folic acid for 24 months versus placebo

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged elder than 70 years old; 2. Clinical diagnosis of MCI; 3. Homocysteine greater than 13umol/L; 4. Caregiver (personal contact at least once a week).

Exclusion criteria

Exclusion criteria: 1. Demenita; 2. Hypothyroidism; 3. B12 200 umol/L.

Design outcomes

Primary

Measure	Time frame
Cognitive improvement (CDR score);	—

Secondary

Measure	Time frame
CDR sum of scores;neurocognitive test;depression scale;	—

Countries

China

Contacts

Public ContactProf. Timothy Kwok

tkwok@cuhk.edu.hk+852 2632 3145

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026